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Robustoxin, the lethal neurotoxin isolated from the venom of the male Sydney funnel-web spider, Atra.u 
robustus, is of unique structural type and physiological mode of action. The primary structure of this 4% 
residue peptide was determined to be H,N-Cys-Ala-Lys-Lys-Arg-Asn-Trp-Cys-Gly-L~~-Asn-Glu-Asp-Cys- 
Cys-Cys-Pro-Met-Lys-C~~-Ile-Tyr-Ala-Trp-Tyr-Asn-Gln-Gin-Gly-S~~-Cys-Gln-Thr-Thr-Ile-Thr-Gly-Leu- 
the-Lab-Lys-Cys-H. The dispostition of disulphide-bridged cysteine residues at both the ammo- and car- 
boxy-termini and as a triplet at residues 14-16 appears to have no precedent amongst neurotoxins. 
Spider venom Amino acid sequence Polypeptide neurotoxin Atrax robustus Robustoxin 
1. INTRODUCTION 
The Sydney funnel-web spider, A trax robustus, 
may be considered to be the world’s most 
dangerous spider because of its strength and ag- 
gressiveness, the Iethai potency of its venom, its 
nocturnal habit, and its penchant for invading 
houses. At least 13 deaths attributed to the bite of 
the male spider have been recorded since 1927 [I]. 
Its distribution coincides with the metropolitan 
area of Australia’s largest city. Unlike other 
poisonous spiders, male rather than female A. 
robustus is dangerous to man [Z]. Male A. 
robustus envenomation is also unusual in that it 
has little effect on non-primates, but is potentially 
lethal to newborn mice and primates, including 
man. The symptoms of human envenomation are 
bizarre and include [3] Iacrimation, salivation, 
muscle fasciculation, massive pulmonary oedema, 
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Abbreviation: RCM, reduced carboxymethylated 
profound vasoconstriction and hypertension 
followed by hypotension, leading ultimately to 
death. 
Recently, we isolated the lethal neurotoxin, 
robustoxin, from the venom of male A. robustus 
f4f and obtained its N-terminal sequence. The 
venom of female spiders did not appear to contain 
significant quantities of robustoxin [2]. In 
monkeys, robustoxin displayed all of the activities 
observed due to envenomation by crude venom. Its 
LDso, determined by subcutaneous injection in 
newborn mice, was 0.16 mg+kg-‘. We have now 
determined its complete amino acid sequence and 
found that this sequence does not appear to have 
homology with other neurotoxins and that 
robustoxin is of unique structura1 type amongst 
neurotoxins. We had previously found 141 by gel 
permeation chromatography that robustoxin had 
an apparent MI of 5800, but had discounted this 
result as robustoxin was a very basic peptide (PI 
10.2), and such peptides tend to give a low result 
in this type of determination. Based on yields ob- 
tained in amino acid analyses, we had tentatively 
assigned an Mr of 9650 to robustoxin. No free cys- 
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teine residues were detected. The extensive 
disulphide bridging indicated that robustoxin was 
a highly folded peptide. 
2. EXPERIMENTAL AND RESULTS 
Robustoxin was isolated and purified from 
crude male A. robustus venom as previously 
described [4]. It was converted to its RCM- 
derivative according to the procedure of Kung et 
al. [.5]. The amino acid sequence of RCM- 
robustoxin was determined directly with a model 
47QA automatic gas-phase protein sequencer (Ap- 
plied Biosystems Inc., Poster City, CA) essentially 
by the methods of Hewick et al. (61. Their standard 
Edman degradation sequenator program with only 
minor changes was used in our first run. 20 nmol 
of RCM-robustoxin in 0.1 Vo (v/v) trifluoroacetic 
acid was used in each of two uninterrupted runs. In 
the second run the temperature in the sequencer 
cartridge was held at 50°C (44’C in first run) and 
the time of cleavage for the proline at residue 17 
was increased from 15 min to 2 h. Essentially the 
same results were obtained in the two runs, 
however. Sequencing ceased after the 42nd residue 
and it was concluded that robustoxin contains only 
42 amino acid residues, half the number previously 
considered 141, and four disulphide bridges. The 
complete amino acid sequence of rabustoxin (Mr 
4887) was found to F; HZN-Cys-Ala-Lys-Lys-Arg- 
Asn-Trp-Cys-G&-Lys-Asn-Glu-Asp-Gys-Cys-Cys-Cys- 
Pro-Met-L$s-Cys-Ile-Tyr-Ala-Trp-Tyr-Asn-Gln- 
Gl~-Go-Ser-~ys-Gln-Thr-Thr-Ile-Thr-Gly-Leu- 
Phe-Lys-Lys-Cys-H. The earlier N-terminal se- 
quence ]4] is corrected by this complete one in two 
respects. Residue 15 (the N-terminus is residue 1) 
was shown to be Cys instead of Be, and residue 17 
was Pro rather than Thr. The amino acid composi- 
tion (table 1) of robustoxin was in complete agree- 
ment with the sequence. 
Carbaxy-terminal analysis of RCM-robustoxin 
was performed by a modification of the method of 
Liberatore et al. [!?) using carboxypeptidase Y im- 
mobilized on Sepharose 4B (Pierce Chemical Co.) 
at pH 6.0, since the RCM-toxin was not sufficient- 
ly solubIe at the usual pH for this enzyme of 8.0. 
The RCM-toxin f&5 mg) was dissolved in 2.5 cm3 
of 0.2 M acetic acid and then buffered to pH 6.0 
with ~-ethylmorpholine~ Carboxypeptidase Y 
(25 ,& was added and the mixture was held at 
Table t 
Ammo acid COMpOSitiOR of robustoxin 
Amino 
acid 
From the Molar ratio (hydrolysis time, h) 
sequence 
24a 24 48 60 
LYS 
Arg 
Asx 
Thr 
Ser 
Ghi 
Pro 
Cly 
Ala 
CYS 
Met 
Be 
Leu 
Tyr 
Phe 
Trp 
Total 
6 
t 
4 
3 
f 
4 
I 
3 
2 
8 
1 
2 
1 
2 
f 
2 
42 
5.6 
1.2 
3.9 
3.2 
0.7 
4.2 
13 
3.2 
2.0 
1.6 
b 
1.9 
1.0 
2.f 
1.1 
5.6 
1.1 
3.8 
3.1 
0.6 
3.9 
1.6’ 
3.3 
2.1 
1.4 
1.1 
1.8 
1.0 
2.0 
1.1 
I.8 
5.8 5.3 
1.1 1.0 
3.7 3.9 
3.0 2.6 
0.6 0.5 
4.x 4.1 
1,@ 1.5< 
3.1 3.2 
2.0 2.2 
6.6 5.8 
1.0 1.1 
1.9 1.8 
1.0 1.0 
2.1 2.0 
1.0 1.1 
’ Oxidised with performic acid before hydrolysis 
b Not quantified 
’ Not accurate in this analysis. A value of 1 .O for proline 
was found [4] by ninhydrin detection, when allowance 
is made for halving the apparent M, of robustoxin 
assigned previously 
RCM-robustoxln (0.5 mg) was mixed with 2 cm3 of 
constant boiling HCi (Pierce Chemical Co,) and 
5 mg.cme3 of phenol. Hydrolysis was carried out in 
evacuated seaIed tubes at 108°C. The hydrolysate was 
dried in a stream of ultrapure nitrogen, dissolved in 
0.2 M sodium citrate at pH 3.1, and centrifuged. The 
supernatant was subjected tr, analpis using the Waters 
Associates amino acid analysis HPLC systems through 
post-column derivatization with o-phthalaldehyde 171. 
Blank hydrolyses were performed in the absence of 
robustoxin. The tryptophan content was analysed 
spectrophotometrically by the procedure of Goodwin 
and Morton [S]. The content of cysteine was determined 
after performic acid oxidation of the toxin. Performic 
acid was prepared by mixing I ~0130% (w/w) hydrogen 
peroxide with 9 vofs 98% (w/w) formic acid. 
Robustoxin (0.5 mg) was dissolved in 2 cm’ of the 
performic acid and the mixture was held at ambient 
temperature for 18 h. ft was diluted with water, 
lyopbiIised, hydrofysed and subjected to amino acid 
analysis as above 
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35°C. Aliquots of the mixture were removed, 
lyophilized and redissolved in 0.2 M sodium citrate 
buffer at pH 3.1. These were analysed for free 
amino acids by HPLC [7]. After 3 days incubation 
only carboxymethylcysteine and lysine were 
detected in the digest in agreement with the car- 
boxy terminal of -Lys-Cys-H found in the se- 
quence of robustoxin. 
There does not appear to be any precedent, at 
least among neurotoxins, for the location of 
disulphide-bridged cysteine residues at both the 
amino- and carboxy-termini of a polypeptide and 
for the grouping of three of these consecutively (at 
residues 14-16). These features and the low &I, of 
robustoxin distinguish it as a neurotoxin of a new 
structural type. Drs W. Barker and L. Hunt 
searched the database of the National Biomedical 
Research Foundation at Georgetown University, 
USA, and found no significant homology to any 
sequence there, although there were some weak 
similarities to other cysteine-rich neurotoxins and 
phospholipases from various venoms. Our in- 
vestigations are continuing into the secondary 
structure of this potent neurotoxin and to the rela- 
tionship between its structure and physiological 
activity. 
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